University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln
US Army Research

U.S. Department of Defense

2010

Time and degree of glycemic derangement are associated with
increased mortality in trauma patients in the setting of tight
glycemic control
Michael G. Corneille
University of Texas Health Science Center at San Antonio, Corneille@uthscsa.edu

Celina Villa
University of Texas Health Science Center at San Antonio

Steven Wolf
University of Texas Health Science Center at San Antonio

Joel E. Michalek
University of Texas Health Science Center at San Antonio

Inkyung Jung
University of Texas Health Science Center at San Antonio
See next page for additional authors
Follow this and additional works at: https://digitalcommons.unl.edu/usarmyresearch
Part of the Operations Research, Systems Engineering and Industrial Engineering Commons

Corneille, Michael G.; Villa, Celina; Wolf, Steven; Michalek, Joel E.; Jung, Inkyung; Wade, Charles E.; Meyers,
John G.; Dent, Daniel L.; Mueller, Deborah; and Stewart, Ronald M., "Time and degree of glycemic
derangement are associated with increased mortality in trauma patients in the setting of tight glycemic
control" (2010). US Army Research. 118.
https://digitalcommons.unl.edu/usarmyresearch/118

This Article is brought to you for free and open access by the U.S. Department of Defense at
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in US Army Research by an
authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

Authors
Michael G. Corneille, Celina Villa, Steven Wolf, Joel E. Michalek, Inkyung Jung, Charles E. Wade, John G.
Meyers, Daniel L. Dent, Deborah Mueller, and Ronald M. Stewart

This article is available at DigitalCommons@University of Nebraska - Lincoln: https://digitalcommons.unl.edu/
usarmyresearch/118

The American Journal of Surgery (2010) 200, 832– 838

Time and degree of glycemic derangement are associated
with increased mortality in trauma patients in the
setting of tight glycemic control
Michael G. Corneille, M.D.a,*, Celina Villa, M.D.a, Steven Wolf, M.D.a,
Joel E. Michalek, Ph.D.b, Inkyung Jung, Ph.D.b, Charles E. Wade, Ph.D.c,
John G. Myers, M.D.a, Daniel L. Dent, M.D.a, Deborah Mueller, M.D.a,
Ronald M. Stewart, M.D.a
a

Departments of Surgery, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr, San Antonio, TX
78229, USA; bDepartment of Epidemiology and Biostatistics, University of Texas Health Science Center at San Antonio, San
Antonio, TX; cUS Army Institute of Surgical Research, Medical Research and Materiel Command, Fort Sam Houston, TX
KEYWORDS:
Glucose;
Glycemic control;
Hyperglycemia;
Trauma;
Hypoglycemia;
Critically ill

Abstract
BACKGROUND: Tight glucose control (TGC) may reduce mortality in critically ill trauma patients.
We hypothesize that euglycemia is beneficial, and a measure considering time and degree of hyperglycemia is most associated with mortality.
METHODS: We performed a review of intensive care unit trauma patients admitted for more than 3
days between January 2005 and December 2007 on a TGC protocol with a goal of 80 to 110 mg/dL.
Hyperglycemic, hypoglycemic, and euglycemic time ranges, and area of interpolated curves above and
below 80 to 110 mg/dL were assessed. Associations with mortality were based on logistic regression
models adjusted for age, injury severity score, and admission Glasgow Coma Scale score.
RESULTS: A total of 546 patients were identified, and 68 (13%) died. Time spent as hyperglycemic
(P ⫽ .29) and hyperglycemic area under the curve (P ⫽ .58) were not associated with mortality;
hyperglycemic area/time (P ⫽ .01) was associated with mortality. Regarding hypoglycemia, area over
the curve (P ⫽ .009) and time spent as hypoglycemic (P ⫽ .002) were associated with mortality.
CONCLUSIONS: TGC prevents prolonged, high degrees of hyperglycemia; avoiding hypoglycemia
likely provides mortality benefit for trauma patients.
© 2010 Elsevier Inc. All rights reserved.
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Stress hyperglycemia occurring in critically ill intensive
care unit (ICU) patients has a well-documented association
with morbidity and mortality.1,2 The association between
high blood glucose and increased mortality has been shown
in patients after trauma,3–9 burn,10 cardiac surgery,11,12
myocardial infarction,13–16 and stroke,17,18 as well as for
general ICU patients.19 –21 Increased blood glucose levels
above the normal range of 80 to 110 mg/dL are common in
a wide variety of acute illnesses, irrespective of previously
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diagnosed diabetes.13,17,20,22 In an effort to mitigate the
effects of hyperglycemia, tight glucose control protocols
have been implemented in ICUs worldwide.23–29 Common
to these protocols is use of insulin to try to convert a
hyperglycemic patient to a normoglycemic patient. There is
wide inconsistency, however, in the methods used to describe glucose control and in the glucose end point, which
showed a mortality or morbidity improvement. In her landmark study, Van den Berghe et al30 measured 6 AM glucose
level to assess glycemic control. Since then, admission ICU
glucose level,4,7,31 average daily glucose level,9 maximum
glucose level,4 average overall glucose level,4,20 and time in
range29,32 also have been used to assess glycemic control.
However, other investigators have found that these results
have not been consistent.33,34 Volgelzang et al35 support the
idea that there are potentially inherent deficiencies in these
methodologies, for instance, the use of mean glucose concentration as a predictor of morbidity and mortality likely
incurs bias because of unequal time distribution between
measurements. They described use of the “hyperglycemic
index,”35 which measures the area between the upper limit
of normal and the curve of interpolated glucose values
above the normal range, to show that area under the curve
has a superior relation with mortality compared with other
glucose indexes. However, this methodology does not incorporate hypoglycemia and has not been applied to critically ill patients routinely placed on a tight glucose control
(TGC) protocol. Thus, we hypothesize that a measure that
includes both time and degree of glycemic derangement
eliminates the bias of using each independently and would
better predict mortality than either would alone in a setting
of routine TGC.

Methods
This was a single-center, retrospective review of patients
age 18 years and older admitted after a trauma to University
Hospital (San Antonio, TX), a Level I Trauma Center,
between January 2005 and December 2007. The surgical
trauma ICU has had a TGC protocol in place since 2005.
Subjects were identified by trauma registry query and blood
glucose values were obtained by query of the hospital electronic medical record. Patients with an injury severity score
(ISS) of less than 9 and an ICU length of stay of less than
3 days were excluded. The study protocol was approved by
the UTHSCSA Institutional Review Board. We collected all
glucose values, demographics, diagnoses, mechanism of
injury, medical history including diabetes, length of ICU
stay, clinical course, and disposition. Hyperglycemia was
defined as any value greater than 110 mg/dL; hypoglycemia
was defined as less than 80 mg/dL. Severe hypoglycemia
was defined as 40 mg/dL or less regardless of symptoms or
lack thereof. Glucose parameters assessed were ICU admission values; average morning glucose level (6:00 AM reading); average daily glucose level; amount of time in the
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Figure 1 A typical interpolated curve from which areas and
times were calculated.

hyperglycemic, hypoglycemic, and euglycemic ranges; and
area hyperglycemic (area under interpolated curves above
110 mg/dL) and area hypoglycemic (area over interpolated
curves below 80 mg/dL). A representative curve is shown in
Fig. 1.
We used logistic regression models to assess associations
between glucose measures and mortality with and without
adjustment for age, ISS, and admission Glasgow Coma
Scale (GCS) score. Associations were made based on the
first 72 hours of ICU stay so that all patients contributed to
the logistic regression model and to avoid survivor bias. We
summarized continuously distributed outcomes by the
mean ⫾ 1 standard deviation or the median and the first and
third quartiles and contrasted survivors with nonsurvivors
using Wilcoxon tests. We contrasted survivors with nonsurvivors on binary outcomes with the Fisher exact test. All
statistical testing was 2-sided with a significance level of
5% and SAS version 9.2 for Windows (SAS Institute, Cary,
NC) was used throughout.

TGC protocol
At admission to the surgical ICU, all patients received 3
point-of-care capillary fingerstick glucose tests 4 hours
apart. If 1 value was greater than 150 mg/dL or 2 values
were greater than 120 mg/dL, the patient was started on a
continuous intravenous insulin infusion to keep blood glucose values between 80 and 110 mg/dL. Blood glucose level
was checked hourly on the insulin drip and adjusted until it
remained stable for 4 hours. Once stable, the blood glucose
level then was checked every 2 hours. Point-of-care glucose
testing was performed by medical technicians using the
Accu-Chek Inform System (F. Hoffmann-La Roche, Ltd,
Basel, Switzerland). Insulin therapy was held for glucose
values less than 70 mg/dL, and dextrose was administered
for values less than 50 mg/dL. Regarding nutritional ther-
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apy, the standard of care in the ICU was to institute enteral
feeding as soon as possible.

Table 2

Glucose value characteristics by outcome
Survivors
n ⫽ 478

Results
Demographics
A total of 546 subjects were identified. Most patients
were male (69%; 378 of 546), with a mean age of 50 years
(standard deviation, 20.2 y). The proportion of patients with
a history of diabetes (Table 1) was similar between survivors and nonsurvivors (24% survivors and 27% nonsurvivors; P ⫽ .65). Presence of head injury was significantly
higher in nonsurvivors (62%) compared with survivors
(48%; P ⫽ .04). Average admission GCS was significantly
lower in the nonsurvivors (7.7 ⫾ 5.5) when compared with
survivors (10.3 ⫾ 5.3; P ⬍ .001). ISS scores were significantly higher in the nonsurvivors (31.7 ⫾ 12.7) compared
with the survivors (24.4 ⫾ 10.2; P ⬍ .001), as well as
Trauma Injury Severity Score (TRISS) (.5 ⫾ .4 and .7 ⫾ .3,
respectively; P ⬍ .001). There were 68 deaths for an overall
mortality rate of 13% (68 of 546). Of these, 21 of 68 were
declared dead according to neurologic criteria.

Glucose measurements

Demographics by outcome
Survivors
n ⫽ 478

Age, y*
Male, n (%)†
History of diabetes,
n (%)†
Traumatic brain
injury, n (%)†
Admit GCS*
ISS*
TRISS*
Injury type†
Blunt, n (%)
Penetrating, n (%)
Hospital length of
stay, d*
ICU length of stay, d*
Days on ventilator*

Nonsurvivors
n ⫽ 68

P
value

49.2 ⫾ 19.6 55.5 ⫾ 23.3
328 (68.6)
50 (73.5)

.03
.48

112 (23.5)

.65

18 (26.5)

229 (47.9)
42 (61.8)
10.3 ⫾ 5.3
7.7 ⫾ 5.5
24.4 ⫾ 10.2 31.7 ⫾ 12.7
.7 ⫾ .3
.5 ⫾ .4
449 (94.1)
28 (5.9)

Admission glucose
level
176 (83.4)
186.9 (84.3)
Average daily
glucose level† 118.4 (31.7)
122.1 (53.5)
ICU average
length of stay
glucose level†
116 (98–146) 108 (94–139.5)
Maximum glucose
level†
215.2 (80.1)
239.6 (101)
Minimum glucose
level†
71.7 (19.4)
66.9 (23)

P
value*
.12
.95

.35
.01
.04

Survivor and nonsurvivor values are expressed as mean (SD or
range).
*Wilcoxon test.
†First 3 days.

In the first 3 days, morning glucose level and average daily
glucose level did not vary significantly between survivors
and nonsurvivors (Table 2); the maximum glucose level was
increased significantly (P ⫽ .01) and the minimum glucose
level was decreased significantly in nonsurvivors (P ⫽ .04).

Logistic regression model

A total of 97,846 glucose measurements were analyzed
with a median of 102 (range, 45–241) measurements per
subject. The median number of daily glucose measurements
per subject was 6.5 (range, 3.9 –11.3). ICU admission glucose level was similar between survivors and nonsurvivors.

Table 1

Nonsurvivors
n ⫽ 68

63 (92.6)
5 (7.4)

.04
⬍.001
⬍.001
⬍.001
.59

17 (10–27)
8 (5.5–17.5) ⬍.001
8 (4–16)
8 (5.5–17)
.39
3(0–11) 7.5 (4–12)
⬍.001

Values in ( ) are ranges unless otherwise noted.
*Wilcoxon test.
†Proportion; compared using the Fisher exact test.

Regarding hyperglycemia, neither area under the curve
(AUC) as hyperglycemic (AUC, .739; P ⫽ .58) nor total
time spent as hyperglycemic (AUC, .739; P ⫽ .29) were
associated with mortality. However, the ratio of area/time
spent hyperglycemic was associated significantly with mortality (AUC, .745; P ⫽ .01).
Regarding hypoglycemia, both AUC as hypoglycemic
(AUC, .752; P ⫽ .009) and time spent as hypoglycemic
(AUC, .758; P ⫽ .002) were associated significantly with
death, but the ratio of area over time spent as hypoglycemic
was not (AUC, .717; P ⫽ .26) (Table 3).

Table 3 Associations between mortality and glucose time
and area summary measures
Measure
Area hyperglycemia
Time hyperglycemia
Area hyperglycemia/
time
Area hypoglycemia
Time hypoglycemia
Area hypoglycemia/
time

Odds ratio (95% CI)

AUC*

P value

1.00 (1.00–1.00)
.991 (.975–1.008)

.739
.739

.58
.29

1.016 (1.004–1.029)
1.004 (1.001–1.007)
1.063 (1.023–1.104)

.745
.752
.758

.01
.009
.002

1.039 (.971–1.112)

.717

.26

Associations for the first 3 days adjusted for age, ISS, and admission GCS score.
*AUC; area under the receiver operator characteristic curve.
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Hypoglycemia
There were 1,139 hypoglycemic (⬍80 mg/dL) values in
373 of 546 (68%) patients in the first 3 days. Over the entire
hospital stay, 4.8% (4,692 of 97,846) of glucose values were
less than 80 and 458 of 546 (84%) individual patients had at
least 1 value less than 80. Severe hypoglycemic (ⱕ40 mg/
dL) values were fewer: 42 glucose values in 32/546 individual patients, a rate of 5.9% in the first 3 days. Over the
entire hospital stay, .14% (140 of 97,846) of glucose values
were 40 mg/dL or less and 89 of 546 (16%) individual
patients had at least one value of 40 or less.

Conclusions
The use of TGC protocols in the care of critically ill
patients has resulted in much effort, research, and expense
since it was first identified that TGC may contribute to an
improvement in mortality rate in critically ill patients. In
this study, we hypothesized that both the overall degree of
hyperglycemia and the time spent as hyperglycemic combined were associated with mortality and that independently
these measures were not. The use of AUC calculations in a
critically ill population was first introduced by Volgelzang
et al35 as the hyperglycemic index. However, the subjects in
their study were not routinely placed on a strict glucose
control protocol. In addition, the hyperglycemic index did
not apply to or quantify hypoglycemia, which is represented
in our calculations as AUC. Thus, our results reflect a
contemporary population of critically ill trauma patients
who had been routinely placed on a TGC protocol.
Although other investigators have shown that time spent
as hyperglycemic is associated with mortality, our data did
not show this association.29,32 We explain this by considering that time spent as hyperglycemic taken by itself does not
give the full picture of a patient’s physiology because
equally timed excursions out of range are not quantified as
large or small. Similarly, if comparing 2 patients with equal
hyperglycemic AUCs, small derangements over a long time
would be the same as large derangements over a short time.
These patients likely would have very different physiologies
and different mortality expectations. By indexing area/time
spent as hyperglycemic, the degree of derangement per unit
of time can be quantified, hence the finding that a high
degree of hyperglycemic derangement/time is associated
with mortality.
Regarding hypoglycemia, time spent as hypoglycemic
was associated with mortality, suggesting that any amount
of time spent hypoglycemic was detrimental. Area hypoglycemic also was predictive of mortality, suggesting that
any hypoglycemia that a patient incurred was detrimental.
That area/time was not predictive of mortality suggests that
it is not the degree per unit of time that impacts mortality,
but any hypoglycemia at all. The finding that any hypoglycemia (⬍80 mg/dL) is associated with mortality is noteworthy because hypoglycemia usually is considered clinically
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significant at less than 40 mg/dL or with significant sequelae
such as seizures, cardiac dysrhythmia, or coma. That 3
recent large studies ceased enrolling patients before completing enrollment goals owing at least in part to high rates
of hypoglycemia illustrates the concern that all hypoglycemia may be detrimental in critically ill patients.36 The rates
of severe hypoglycemia (ⱕ40 mg/dL) encountered overall
in our study (16%) were much higher than the 8.7% rate
reported in the GluControl trial or the 6.8% reported in the
Normoglycemia in Intensive Care Evaluation–Survival Using Glucose Algorithm Regulation (NICE-SUGAR) trial;
although the rate during the first 3 days, 4.8%, is consistent
with these other studies.37,38 Although 16% may seem comparatively high at first glance, these values are not indexed
by number of patient days or presented as a proportion of
total glucose values obtained. When considered as a proportion of total glucose values, our rate of hypoglycemia
(ⱕ40 mg/dL), .14% (140 of 97,846), is quite low.
Based on our data, we propose that an ideal TGC protocol for critically ill trauma patients admitted to the ICU
for longer than 3 days would avoid large hyperglycemic
excursions, but allow for much smaller excursions throughout the ICU stay and avoid any hypoglycemia. To achieve this, we suggest that the ideal TGC protocol must control increased glucose values aggressively and early with
screening and liberal use of intravenous insulin drips and
then address increased glucose levels throughout the hospital stay before they become large excursions. Furthermore,
to reduce the amount of hypoglycemia, the goal range must
have a greater lower control limit. The resulting protocol
would aim for a higher lower limit such as 100 mg/dL and
increase the difference between the upper and lower limits
of normal from 30 mg/dL to perhaps 50 mg/dL such that
rather than 80 to 110 mg/dL, the range would become 100
to 150 mg/dL. The resulting glucose curve would have
fewer significant excursions from control.
These recommendations are speculations based on our
data and would need to be tested in a similar population to
ours. It must be kept in mind that our TGC protocol is
designed with the intention of maintaining glucose levels
between 80 and 110 mg/dL, and our subject’s glucose values were influenced by patient physiology, critical illness,
and insulin dosing behavior to keep glucose values in the 80
to 110 mg/dL range.
Although the range of 80 to 110 mg/dL has largely become
the standard, increased incidences of hypoglycemia have
caused investigators to challenge this glycemic goal.36 –38
Recognizing that the prospective randomized trials after
Van den Berghe et al30 trial have failed to produce the same
mortality reduction and that the ideal range for blood glucose level in critically ill patients is unclear, the NICESUGAR study investigators compared mortality in patients
on a TGC regimen with a range of 81 to 108 mg/dL with a
conventional glucose control range of less than 180 mg/dL.
Based on a primary end point of 90-day mortality, they
showed that there was a statistically significant increase in

836

The American Journal of Surgery, Vol 200, No 6, December 2010

mortality associated with their TGC protocol and glucose
range. They also reported a significantly higher rate of
severe hypoglycemia (ⱕ40 mg/dL) in the TGC group (6.8%
vs .5%). The investigators concluded that “intensive glucose
control increased mortality among adults in the ICU.”38
Although the data in the NICE-SUGAR study well showed
that the protocol used to achieve conventional glucose control was superior to the one used to achieve TGC, this study
compared only 2 protocols and glucose ranges. Certainly,
both achieved better control than would have been achieved
without a protocol, but the rate of hypoglycemia in the tight
control group was an order of magnitude higher than in the
conventional group. It could be that any benefit that was
achieved by TGC was mitigated by the impact of hypoglycemia. We suggest that any future trial that aims to establish
either the benefit of or optimum range of TGC should
consider each independently and aim to control hyperglycemia and aggressively avoid hypoglycemia.
Our study had limitations inherent in any retrospective
study. Specific to this type of study, which aims to correlate
glucose control and outcome, it is impossible to clearly
delineate the specific contribution of all the factors that
contribute to a patient’s glucose control. These include but
are not limited to the TGC protocol, the often-changing
patient circumstances and physiology, as well as nursing
response and behavior, which leads to an insulin dose. Some
of these factors will be mitigated by closed-loop glucose
measuring and insulin dosing as well as nursing decision
support for insulin dosing. An additional consideration is
the contribution that brain injury contributes to mortality in
critically ill trauma patients. Our logistic regression model
was based on the first 72 hours of ICU stay so that all
patients were able to contribute to the model. In eliminating
this survivor bias, the model still shows that glycemic derangement is predictive of mortality. It may be that traumatic brain injury causes glycemic derangement or vice
versa. We cannot discern this from a retrospective study. It
is not known whether TGC is of benefit in this population
and if so in what range. Likely, patients who are so severely
brain injured that they progress to brain death do not benefit
from TGC, however, to exclude them from analysis would
be to exclude a population who was maintained on a TGC
protocol. Further data are necessary to make clear which
populations benefit most from TGC.
Our study contributes to the evidence that poor glucose
control is associated with mortality. It cannot be determined
from retrospective data whether poor glucose control is a
marker for poor outcome or a cause of it. Although there
have been many proposed measures to show adequate glycemic control, we believe that a standardized variable or set
of variables would allow for better comparisons between
populations and establish clearly whether TGC does in fact
save lives. It also would allow a better understanding of the
true cost to save 1 life using a TGC protocol. We believe
that calculating both the AUC hyperglycemic and AUC
hypoglycemic are important metrics to evaluate a patient’s

glycemic control as well as the effectiveness of a TGC
protocol.
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Discussion
Walter L. Biffl, M.D. (Denver, CO): In surgery and
critical care few studies have had such immediate and farreaching impact on practice as that of Van den Berghe and
colleagues30 in 2001. Based on the results of this singleinstitution clinical trial, TGC in the range of 80 to 110
g/dL became standard practice in ICUs and, in fact, was
endorsed by numerous professional organizations. But there
remained some unresolved issues related to the optimal
clinical setting, patient population, glucose control regimen,
and target glucose level. Based on their findings, the authors
have suggested that the method of calculating AUC including both time and glucose measurement is a superior metric
to assess glucose control and predict mortality in their
patients. In order to put this in context, I have just a couple
of questions. First, regarding the patient population, half the
patients in this study had traumatic brain injury (TBI), and
among the nonsurvivors, over 60% had TBI. Many patients
with severe TBI are going to die of that injury regardless of
glucose control or any interventions in the ICU. What was
the attributable cause of death in the patients who died, and
how does it affect your conclusions if you exclude the TBI
deaths? Second, it is difficult to maintain perfect glucose
control in the range of 80 to 110. Regarding the consequences of less tight glucose control, you point out that
multiple small derangements on the hyperglycemic side are
not associated with mortality, but you note that any hypoglycemia is detrimental. Consequently, you suggest in your
manuscript a more relaxed target of a 100 to 150 and this is
supported by recent literature. In fact, I was surprised that in
the manuscript you did not discuss the recent NICE SUGAR
trial, which threw a bit of cold water on the concept of TGC
in the 80 to 110 range. With more relaxed glucose control,
you would likely have less hypoglycemia. Given that your
study period ended in December of 2007, I was wondering
whether you had in fact changed your regimen or if you are
still attempting TGC (80 –110)? In the end, I think your
conclusion is the most valuable take-home lesson: that we
need to avoid prolonged high degrees of hyperglycemia and
avoid all hypoglycemia.
Michael Corneille, M.D. (San Antonio, TX): With regard to traumatic brain injury, we certainly recognize that,
and that is the most common cause for mortality in our ICU
and this is why we did a logistic regression model to try to
control for brain injury using the admission Glasgow Coma
Score to do that. We will certainly have to go back and look
at our data to ascertain what was the attributable cause of
death in those that did die. With regard to hypoglycemia and
hyperglycemia, I believe that they are independent. I think
there has been some benefit demonstrated to reducing hyperglycemia, but I think there is also some detriment from
hypoglycemia. So I think that they are 2 independent functions and whatever is done to control glycemia in the ICU
needs to find the point at which there is maximum benefit
from reduction in hyperglycemia and with elimination of

838

The American Journal of Surgery, Vol 200, No 6, December 2010

detriment from hypoglycemia. You asked if we changed our
protocol. We have not yet because we have not found
anyone that showed us what a better one is. There have been
many attempts and many different ranges have been published in the literature, but there has been no real scientific
effort to find out both what is the best glucose range for
patients in the ICU and, secondly, what type of glycemic
control protocol gets you there best. So we have not
changed our range in our ICU.
Fred Moore, M.D. (Houston, TX): Echoing Dr. Biffl,
the Van den Berghe et al30 trial has had this tremendous
impact, but nobody has been able to repeat it. Paul Merritt
just did a meta-analysis and there was an important confounding variable. In the Van den Berghe et al30 trial they
started total parenteral nutrition and these patients are getting heavy glucose loads. Now, that could be that insulin
with high glucose infusion is actually an anabolic thing, so
it could prevent breakdown of muscle, but it also could
prevent serious hypoglycemic episodes. And that is the
reason everybody is backing away from the 80 to 110
because the incidence of severe hypoglycemia less than
40 is significant, up to 10% of patients. So my questions

are 2: what is your practice as far as nutrition in your
ICU? Are you giving total parenteral nutrition early? I
suspect not. And what is the incidence of severe hypoglycemia in your patients below 40?
Dr Michael Corneille: With regard to nutrition we
strongly prefer enteral nutrition to parenteral nutrition.
And so, no, it is not a routine that these patients are on
total parenteral nutrition for nutrition. We feed as early as
we can and prefer an enteral route. Also, I agree with you
that it may be, as Van den Berghe et al30 titled their
paper, intensive insulin therapy, that is of benefit; although reduction in hyperglycemia has been shown in
several studies to have an association with improvements
in morbidity and mortality. With regard to severe hypoglycemia, I will have to go back and quantify, but in our
unit, anecdotally, I cannot remember a case of a patient
having a seizure or some other untoward consequence of
severe hypoglycemia and I think our data show that it is
not necessarily severe hypoglycemia, it is really any
hypoglycemia. Now, whether that is underlying patient
physiology that creates that association or not, that is our
protocol. We cannot quite tease that out.

